Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00088829 · ClinicalTrials.gov registry record · Phase 2
Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT00088829: Clinical Trial Phase 2 study, sponsored by Georgetown University.
NCT00088829 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 22 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00088829, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have unresected breast cancer.
Primary Outcome
Due to the early termination of the study, this data for this outcome was not collected.
Interventions
- GENETIC microarray analysis
- DRUG Paclitaxel
- PROCEDURE biopsy
- DRUG paclitaxel
- PROCEDURE neoadjuvant therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2001-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Why NCT00088829 stopped before completion
NCT00088829 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (83% lower).
The record links to 0 conditions, and to 5 interventions - of which microarray analysis is the first listed.
NCT00088829 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00088829 about?
NCT00088829 is a clinical study titled "Genetic Testing in Predicting Response to Paclitaxel in Women With Breast Cancer". RATIONALE: Analyzing genes for changes before and after chemotherapy may help doctors predict a patient's response to treatment and help plan the most effective treatment. PURPOSE: This clinical trial is studying how well genetic testing works in predicting response to paclitaxel in women who have ...
What is the current status of trial NCT00088829?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2001-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00088829?
The interventions under investigation include: microarray analysis (GENETIC), Paclitaxel (DRUG), biopsy (PROCEDURE), paclitaxel (DRUG), neoadjuvant therapy (PROCEDURE).
Who is sponsoring clinical trial NCT00088829?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00088829's enrollment target sits among peer trials
22 1790th of 2000 higher than 207 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia